Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler acquired 100,000 shares of the business’s stock in a transaction that occurred on Friday, May 11th. The shares were purchased at an average price of $19.33 per share, with a total value of $1,933,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Accelerate Diagnostics opened at $22.15 on Friday, Marketbeat reports. The company has a current ratio of 27.80, a quick ratio of 26.44 and a debt-to-equity ratio of 0.65. Accelerate Diagnostics, Inc. has a 1-year low of $20.45 and a 1-year high of $21.25.
Accelerate Diagnostics (NASDAQ:AXDX) last announced its earnings results on Wednesday, May 9th. The medical research company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.05. The company had revenue of $0.80 million during the quarter, compared to analyst estimates of $2.64 million. Accelerate Diagnostics had a negative net margin of 1,568.29% and a negative return on equity of 51.23%. analysts forecast that Accelerate Diagnostics, Inc. will post -1.38 EPS for the current fiscal year.
Several equities research analysts recently issued reports on the stock. BidaskClub upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday. Finally, BTIG Research restated a “hold” rating on shares of Accelerate Diagnostics in a research report on Sunday, February 18th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $33.00.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.